At the end of January, the small-cap biotechnology company AVEO Oncology (AVEO) updated investors on the delayed timeline for filing with FDA for their lead compound tivozanib. This news led to a … [Read more...] about Evaluating the Merits of AVEO’s Potential Purchase
2019 is undoubtedly the year of gene editing. All three major gene editing biotechnology companies have kicked the year off with monumental studies. As the results of these experiments get published, … [Read more...] about Sangamo (NASDAQ: SGMO) Vs. CRISPR Therapeutics (NASDAQ: CRSP): The Best Gene Editing Stock
From designer babies to malaria-resistant mosquitoes, a future where humans can dive into the basic building blocks of all life and manipulate it for our advantage is not too far away. Startups, … [Read more...] about Illumina: Growth at a Fair Price?
Today Adma Biologics (Nasdaq: ADMA) sold off ~10% closing at $3.50. Most of us already in Adma were not phased. Personally, I saw this as a healthy pullback. Since February 1st ADMA has gained 25% … [Read more...] about ADMA Presents Potential Entry For Investors On The Sideline
Amarin (Nasdaq: AMRN) made perhaps the biggest splash in the small-cap biopharmaceutical space last year by announcing trial results from its long-running REDUCE-IT study. The company has a market cap … [Read more...] about Amarin Corporation – A Whale of a Story
Geron Corporation (Nasdaq: GERN) is a clinical stage pharmaceutical company with a current market cap of just over $300 million. Geron has one drug in its pipeline, a telomerase inhibitor called … [Read more...] about Geron: The Neverending Story
Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
Last fall, Verastem Oncology (NASDAQ: VSTM) received FDA-approval for its first drug, Copiktra, an oral monotherapy for the treatment of relapsed or refractory chronic lymphotic leukemia, small … [Read more...] about Verastem Oncology: Looking for a Port in the Storm
I have recently received many questions on the micro-cap stock Sesen Bio (Nasdaq: SESN). This small company is attempting to make a big name for itself in the area of non-muscle invasive bladder … [Read more...] about Sesen Bio: Are the VISTA Results Up to Par?
Acquisitions in pharmaceutical industry staying at an elevated paceStrong balance sheet even before having any drugs approved for salePromising lentiviral genetic treatment platformSignificant … [Read more...] about Acquisition Targets: Could Bluebird Be In Season?